UPPER LIMB REPLANTATION IN SEVERE COMBINED TRAUMA COMPLICATED BY TRAUMATIC SHOCK (A CASE REPORT)

Authors

Keywords:

replantation, upper limb, combined trauma, traumatic amputation, microsurgery, osteosynthesis.

Abstract

Introduction. Among open limb injuries, combined bone-and-vascular trauma is one of the most severe, being associated with a high rate of postoperative complications, amputations and fatal outcomes. Complete traumatic amputations of large limb segments – particularly traction injuries with a crushing component – pose a special challenge for establishing indications for replantation, which is further aggravated by concomitant injuries.
Aim. To demonstrate the feasibility and to substantiate the surgical strategy of successful upper limb replantation in a patient with severe combined trauma complicated by traumatic shock.
Brief case history. A 16-year-old male patient was admitted within the first hour after a road traffic accident with a complete traumatic traction amputation of the left upper limb at the level of the lower third of the arm, combined with closed chest trauma and pneumothorax, traumatic brain injury, multiple facial skeleton fractures, right upper limb fractures and grade II traumatic shock. After anti-shock measures and hemodynamic stabilization, replantation of the left upper limb was performed as the first stage (duration 5 h 35 min), followed by a series of staged reconstructive operations.
Discussion. Prioritizing replantation as the most complex and traumatic intervention, while deferring the remaining operations to subsequent stages, made it possible to preserve the limb as an organ. Six months after the injury, partial recovery of left upper limb function and nearly complete recovery of right upper limb and facial skeleton function were achieved.
Conclusion. Limb replantation in severe combined trauma is feasible and justified in a relatively stable patient without life-threatening injuries. A strictly individualized approach, reliable osteosynthesis and adequate revascularization are decisive. The high regenerative potential of children and adolescents increases the likelihood of a favorable outcome.

References

1. Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057–1082. https://doi.org/10.2337/dci24-0094

2. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 2024;29(1):101133. https://doi.org/10.1016/j.aohep.2023.101133.

3. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022;7(9):851–61. https://doi.org/10.1016/S24681253(22)00165-0.

4. Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of nonalcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021; 75:284–291

5. Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of nonalcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021; 75:284–291

6. Greenhalgh J, Gooding K, Gibbons E, Dalkin S, Wright J, Valderas J, et al. How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis. J Patient Rep Outcomes 2018;2(1):42. https://doi.org/10.1186/s41687-018-0061-6

7. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and pre-vention. Nat Rev Gastroenterol Hepatol 2018;15:11–20.

8. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guid-ance from the American Association for the Study of Liver Dis-eases. Hepatology 2018;67:328–357.

9. Selvaraj EA, Mozes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 2021;75:770-785.

10. Lin X, Mai M, He T, Huang H, Zhang P, Xia E, et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. (2022) 16:537–45. doi: 10.1080/17474124.2022.2083605

12. Matthias AT, Fernandopulle AN, Seneviratne SL. Survey on knowledge of non-alcoholic fatty liver disease (NAFLD) among doctors in Sri Lanka: a multicenter study. BMC Res Notes 2018;11:556.

13. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-689.

14. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-2224.

15. Stan SI, Biciuşcă V, Clenciu D, Mitrea A, Boldeanu MV, Durand P, et al. Te thera-peutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic revi ew. Med Pharm Rep. (2023) 97:12–25. doi: 10.15386/mpr-2629

16. Li B, Zhong P, Zhang X, Li C, Luan M, Chen Y, et al. CYP4A14-PPARα axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD. J Nutr Biochem. (2026) 147:110138. doi: 10.1016/j.jnutbio.2025.110138

17. Wang X, Liang G, Zhou Y, Ni B, Zhou X. Ameliorative effect and mechanism of ursodeoxycholic acid on hydrogen peroxide-induced hepatocyte injury. Sci Rep. (2024)14:4446. doi: 10.1038/s41598-024-55043-3

18. Hwang JS, Lai TH, Kim DR. Targeting lipophagy in liver diseases: impact on oxidative stress and steatohepatitis. Antioxidants. (2025) 14:908. doi: 10.3390/antiox14080908

Published

2026-11-16

Issue

Section

Articles